genz-644282 and Neoplasms

genz-644282 has been researched along with Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for genz-644282 and Neoplasms

ArticleYear
Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9

    Genz-644282 [8,9-dimethoxy-5-(2-N-methylaminoethyl)-2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-one] has emerged as a promising candidate for antitumor agents. This report describes the bone marrow colony-forming unit, granulocyte macrophage (CFU-GM) and tumor cell CFU activity of topoisomerase I (Top1) inhibitors, such as Genz-644282, topotecan, irinotecan/SN-38, and ARC-111, and examines their activity in several human tumor xenograft models.. Colony-forming assays were conducted with mouse and human bone marrow and eight human tumor cell lines. In addition, 29 human tumor cell lines representing a range of histology and potential resistance mechanisms were assayed for sensitivity to Genz-644282 in a 72-hour exposure assay. The efficacy of Genz-644282 was compared with standard anticancer drugs (i.e., irinotecan, docetaxel, and dacarbazine) in human tumor xenografts of colon cancer, renal cell carcinoma, non-small cell lung cancer, and melanoma.. Human bone marrow CFU-GM was more sensitive to the Top1 inhibitors than was mouse bone marrow CFU-GM. The ratio of mouse to human IC(90) values was more than 10 for the camptothecins and less than 10 for Genz-644282, which had more potency as a cytotoxic agent toward human tumor cells in culture than the camptothecins in the colony-forming and 72-hour proliferation assays. Genz-644282 has superior or equal antitumor activity in the human tumor xenografts than the standard drug comparators.. On the basis of preclinical activity and safety, Genz-644282 was selected for development and is currently undergoing phase 1 clinical trial.

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Cells, Cultured; HCT116 Cells; HeLa Cells; HT29 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Models, Biological; Naphthyridines; Neoplasms; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays

2011
Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:8

    Camptothecin derivatives are powerful anticancer drugs because of their ability to trap topoisomerase I (Top1)-DNA cleavage complexes. However, they exhibit clinical limitations due to the instability of their α-hydroxylactone six-membered E-ring structure. In addition, they exhibit bone marrow and intestinal toxicity, especially in adults, and are drug efflux substrates. Here, we report a novel Top1 inhibitor, Genz-644282. We show that Genz-644282 and its metabolites induce Top1 cleavage at similar, as well as unique genomic positions, compared with camptothecin. The compound also induces protein-linked DNA breaks and Top1-DNA cleavage complexes that persist longer after compound removal than camptothecin. Concentration-dependent and persistent γH2AX formation was readily observed in cells treated with Genz-644282, and was present in greater than 50% of the cell population following 24 hours compound exposure. The compound shows partial cross-resistance in cell lines resistant to camptothecin. These cell lines include the human prostate DU145RC0.1 and the leukemic CEM/C2 cells. Limited cross-resistance to Genz-644282 was also found in the Top1 knockdown colon cancer (HCT116) and breast cancer (MCF7) cell lines and in human adenocarcinoma cells (KB31/KBV1) that overexpress (P-glycoprotein, ABCB1), a member of the ATP-binding cassette family of cell surface transport proteins known to confer MDR. Together, our results provide the first molecular and cellular characterization of Genz-644282 and its clinically relevant metabolites.

    Topics: Antineoplastic Agents; Base Sequence; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; HCT116 Cells; Histones; Humans; Naphthyridines; Neoplasms; Topoisomerase I Inhibitors

2011